OverviewSuggest Edit

Celyad is a biopharmaceutical company, specialized in cell therapy and developing of technologies to treat severe diseases with poor prognosis. The Company focuses on immuno oncology, cardiology, and medical devices.

TypePublic
Founded2007
HQMont-Saint-Guibert, BE
Websitecelyad.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Jul 2021)87(-17%)
Job Openings3
Revenue (FY, 2017)€3.5 M(-58%)
Share Price (Sept 2021)€4
Cybersecurity ratingBMore

Key People/Management at Celyad

Michel Lussier

Michel Lussier

Chairman, Non-Executive Director
Filippo Petti

Filippo Petti

Chief Executive Officer/CFO
Frederic Lehmann

Frederic Lehmann

VP Clinical Development and Medical Affairs
Philippe Dechamps

Philippe Dechamps

Chief Legal Officer
Philippe Nobels

Philippe Nobels

VP Human Resources
Marina Udier

Marina Udier

Independent Director
Show more

Celyad Office Locations

Celyad has offices in Mont-Saint-Guibert and New York
Mont-Saint-Guibert, BE (HQ)
2 Rue Edouard Belin
New York, NY, US
60 Broad St Suite 3502
Show all (2)

Celyad Financials and Metrics

Celyad Revenue

Embed Graph
View revenue for all periods
Celyad's revenue was reported to be €3.54 m in FY, 2017 which is a 58.5% decrease from the previous period.
EUR

Revenue (FY, 2017)

3.5m

Revenue growth (FY, 2016 - FY, 2017), %

(58.5%)

Gross profit (FY, 2017)

3.0m

Gross profit margin (FY, 2017), %

85.5%

Net income (FY, 2017)

(56.4m)

EBIT (FY, 2017)

(52.9m)

Market capitalization (9-Sept-2021)

59.0m

Closing stock price (9-Sept-2021)

4.0

Cash (31-Dec-2017)

23.3m

EV

36.3m
Celyad's current market capitalization is €59 m.
EURFY, 2015FY, 2016FY, 2017

Revenue

3.0k8.5m3.5m

Revenue growth, %

284000%(58%)

Cost of goods sold

1.0k53.0k515.0k

Gross profit

2.0k8.5m3.0m
EURFY, 2015FY, 2016FY, 2017

Cash

100.2m48.4m23.3m

Accounts Receivable

549.0k1.4m233.0k

Current Assets

109.4m85.4m36.4m

PP&E

1.1m3.6m3.3m
EURFY, 2015FY, 2016FY, 2017

Net Income

(29.1m)(23.6m)(56.4m)

Depreciation and Amortization

273.0k760.0k966.0k

Accounts Payable

1.1m(740.0k)(2.5m)

Cash From Operating Activities

(27.3m)(24.7m)(44.4m)
EURFY, 2015

Financial Leverage

1.4 x
Show all financial metrics

Celyad Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Celyad Online and Social Media Presence

Embed Graph

Celyad News and Updates

Celyad Oncology Announces September 2021 Conferences Schedule

MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans…

Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium, July 29, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will r…

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

MONT-SAINT-GUIBERT, Belgium, June 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced preliminary data from t…

Celyad Oncology Announces June 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans t…

Global Stem Cell Therapy Market Report 2021-2030 Featuring Anterogen, JCR Pharma, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences, and Gamida Cell

Dublin, May 17, 2021 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. Stem Cell Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030 provides the strategists, marke…

Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium, March 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will …
Show more

Celyad Blogs

Celyad Oncology announces September 2021 Conference Schedule

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development The post Celyad Oncology announces September 2021 Conference Schedule appeared first on Celyad Oncology.

Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

Enrollment continues at dose level three in Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM); next The post Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights appeared first on Celyad Oncology.

Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day

Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM) showed dose dependent engraftment up to dose level The post Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day ap…

Celyad Oncology to Host Virtual Research & Development Webinar on July 20th

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development The post Celyad Oncology to Host Virtual Research & Development Webinar on July 20th appeared first on Celyad Oncology.

Celyad ONcology to Participate at the William Blair Biotech Focus Conference 2021

Mont-Saint-Guibert, Belgium – Celyad ONcology SA ( Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and The post Celyad ONcology to Participate at the William Blair Biotech Focus Conference 2021 appeared first on Celyad Oncology.

Transparency Notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development The post Transparency Notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007) appeared first on …
Show more

Celyad Frequently Asked Questions

  • When was Celyad founded?

    Celyad was founded in 2007.

  • Who are Celyad key executives?

    Celyad's key executives are Michel Lussier, Filippo Petti and Frederic Lehmann.

  • How many employees does Celyad have?

    Celyad has 87 employees.

  • What is Celyad revenue?

    Latest Celyad annual revenue is €3.5 m.

  • What is Celyad revenue per employee?

    Latest Celyad revenue per employee is €40.7 k.

  • Who are Celyad competitors?

    Competitors of Celyad include Bellicum Pharmaceuticals, Alnylam Pharmaceuticals and Sorrento Therapeutics.

  • Where is Celyad headquarters?

    Celyad headquarters is located at 2 Rue Edouard Belin, Mont-Saint-Guibert.

  • Where are Celyad offices?

    Celyad has offices in Mont-Saint-Guibert and New York.

  • How many offices does Celyad have?

    Celyad has 2 offices.